Anti-proliferative actions of N0-desmethylsorafenib in human breast cancer cells

Biochemical Pharmacology

Volumn 86, Issue 3, 2013, Pages 419-427

  Cui, Pei H ^a   Rawling, Tristan ^a,b   Gillani, Tina B ^a   Bourget, Kirsi ^a   Wang, Xiao Suo ^a   Zhou, Fanfan ^a   Murray, Michael ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

Author keywords

Breast cancer cells; MEK ERK signalling; N0 Desmethylsorafenib; Pharmacokinetic drug interactions; Sorafenib

Indexed keywords

ADENOSINE TRIPHOSPHATE; CASPASE 3; CYCLIN D1; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DOXORUBICIN; DRUG METABOLITE; MITOGEN ACTIVATED PROTEIN KINASE; N' DESMETHYLSORAFENIB; N' DESMETHYLSORAFENIB N' OXIDE; N' HYDROXYMETHYLSORAFENIB; N' HYDROXYMETHYLSORAFENIB N' OXIDE; PROTEIN MCL 1; RAF PROTEIN; SORAFENIB; SORAFENIB N' OXIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; CYTOCHROME P450; DRUG DERIVATIVE; NICOTINAMIDE; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BIOTRANSFORMATION; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LIVER MICROSOME; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; BREAST CANCER CELLS; BREAST TUMOR; CELL PROLIFERATION; CELL STRAIN MCF 7; CYP; DMEM; DULBECCO'S MODIFIED EAGLE MEDIUM; ENZYMOLOGY; ERK; ERK KINASE; EXTRACELLULAR SIGNAL-REGULATED KINASE; FEMALE; LC-MS-MS; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; MCL-1; MEK; MEK/ERK SIGNALING; MYELOID CELL LEUKEMIA SEQUENCE-1; N′-DESMETHYLSORAFENIB; PATHOLOGY; PBS; PHARMACOKINETIC DRUG INTERACTIONS; PHOSPHATE-BUFFERED SALINE; PHYSIOLOGY; RADIOIMMUNOPRECIPITATION; RIPA; TUMOR CELL LINE;

BREAST CANCER CELLS; CYP; CYTOCHROME P450; DMEM; DULBECCO'S MODIFIED EAGLE MEDIUM; ERK; ERK KINASE; EXTRACELLULAR SIGNAL-REGULATED KINASE; LC-MS-MS; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; MCL-1; MEK; MEK/ERK SIGNALING; MYELOID CELL LEUKEMIA SEQUENCE-1; N′-DESMETHYLSORAFENIB; PBS; PHARMACOKINETIC DRUG INTERACTIONS; PHOSPHATE-BUFFERED SALINE; RADIOIMMUNOPRECIPITATION; RIPA; SORAFENIB; VASCULAR ENDOTHELIAL GROWTH FACTOR; VEGF;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; MAP KINASE SIGNALING SYSTEM; MCF-7 CELLS; MICROSOMES, LIVER; NIACINAMIDE; PHENYLUREA COMPOUNDS;

EID: 84884557198     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.05.014     Document Type: Article

References (41)

1. Abrams SL, Steelman LS, Shelton JG, Wong EW, Chappell WH, Basecke J, et al. The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. Cell Cycle 2010;9(9):1781-91.
2. Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 1992;13(1): 18-32.
3. Gupta K, Kshirsagar S, Li W, Ramakrishnan S, Gupta P, Law PY, et al. VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling. Exp Cell Res 1999;247(2):495-504. (Pubitemid 29394787)
4. Lang SA, Schachtschneider P, Moser C, Mori A, Hackl C, Gaumann A, et al. Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes. Mol Cancer Ther 2008;7(11):3509-18.
5. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125-34. (Pubitemid 46089673)
6. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378-90.
7. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008;7(10):3129-40.
8. Bonelli MA, Fumarola C, Alfieri RR, La Monica S, Cavazzoni A, Galetti M, et al. Synergistic activity of letrozole and sorafenib on breast cancer cells. Breast Cancer Res Treat 2010;124(1):79-88.
9. Bianchi G, Loibl S, Zamagni C, Salvagni S, Raab G, Siena S, et al. Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anticancer Drugs 2009;20(7):616-24.
10. Ding Q, Huo L, Yang JY, Xia W, Wei Y, Liao Y, et al. Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer. Cancer Res 2008;68(15):6109-17.
11. Baselga J, Segalla JG, Roche H, Del Giglio A, Pinczowski H, Ciruelos EM, et al. Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. J Clin Oncol 2012;30(13):1484-91.
12. Gradishar W, Kaklamani V, Prasad Sahoo T, Lokanatha D, Raina V, Bondarde S, et al. A double-blind, randomized, placebo-controlled, phase 2b study evaluating the efficacy and safety of sorafenib (SOR) in combination with paclitaxel (PAC) as a first-line therapy in patients (pts) with locally recurrent or metastatic breast cancer (BC). Cancer Res 2009;69(24 Suppl.):44.
13. Mardjuadi F, Medioni J, Kerger J, D'Hondt L, Canon JL, Duck L, et al. Phase I study of sorafenib in combination with docetaxel and prednisone in chemonaive patients with metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol 2012;70(2):293-303.
14. Infante JR, Jones SF, Bendell JC, Greco FA, Yardley DA, Lane CM, et al. A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine. Cancer Chemother Pharmacol 2012;69(1): 137-44.
15. Schultheis B, Kummer G, Zeth M, Brendel E, Xia C, Kornacker M, et al. Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors. Cancer Chemother Pharmacol 2012;69(2):333-9.
16. Awada A, Hendlisz A, Christensen O, Lathia CD, Bartholomeus S, Lebrun F, et al. Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours. Eur J Cancer 2012;48(4):465-74.
17. Ghassabian S, Rawling T, Zhou F, Doddareddy MR, Tattam BN, Hibbs DE, et al. Role of human CYP3A4 in the biotransformation of sorafenib to its major oxidized metabolites. Biochem Pharmacol 2012;84(2):215-23.
18. Lathia C, Lettieri J, Cihon F, Gallentine M, Radtke M, Sundaresan P. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol 2006;57(5):685-92.
19. Minami H, Kawada K, Ebi H, Kitagawa K, Kim YI, Araki K, et al. Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. Cancer Sci 2008;99(7): 1492-8. (Pubitemid 351761743)
20. Rawling T, McDonagh AM, Tattam B, Murray M. Synthesis of unsymmetrical biaryl ureas from N-carbamoylimidazoles: kinetics and application. Tetrahedron 2012;68(30):6065-70.
21. Pleiss U, Gerisch M, Seidel D. Syntheses of 2H3, 15N], [14C]NexavarTM and its labeled metabolites. J Labelled Compd Radiopharm 2006;49(7):603-13.
22. Murray M. In vitro and in vivo studies of the effect of vitamin E on microsomal cytochrome P450 in rat liver. Biochem Pharmacol 1991;42(11):2107-14.
23. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193(1):265-75.
24. Prough RA, Burke MD, Mayer RT. Direct fluorometric methods for measuring mixed function oxidase activity. Methods Enzymol 1978;52:372-7.
25. Stearns RA, Chakravarty PK, Chen R, Chiu SH. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes: role of cyto-chrome P4502C and 3A subfamily members. Drug Metab Dispos 1995;23(2): 207-15.
26. Sonesson A, Buur Rasmussen B. In vitro studies investigating the interac-tions between degarelix, a decapeptide gonadotropin-releasing hormone blocker, and cytochrome P450. Basic Clin Pharmacol Toxicol 2011;109(3): 195-202.
27. Zhang WV, d'Esposito F, Edwards RJ, Ramzan I, Murray M. Inter-individual variation in relative CYP1A2/3A4 phenotype influences susceptibility of clozapine oxidation to CYP-specific inhibition in human hepatic microsomes. Drug Metab Dispos 2008;36(12):2547-55.
28. Marden NY, Fiala-Beer E, Xiang SH, Murray M. Role of Activator Protein-1 in the downregulation of the human CYP2J2 gene in hypoxia. Biochem J 2003;373(3):669-80. (Pubitemid 36981077)
29. Plastaras JP, Kim SH, Liu YY, Dicker DT, Dorsey JF, McDonough J, et al. Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res 2007;67(19):9443-54. (Pubitemid 47535934)
30. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006;66(24): 11851-58. (Pubitemid 46094197)
31. Huether A, Ho pfner M, Baradari V, Schuppan D, Scheru bl H. Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma. Biochem Pharmacol 2007;73(9):1308-17. (Pubitemid 46463952)
32. Sutherland RL, Musgrove EA. Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models. Breast Cancer Res 2002;4(1):14-7. (Pubitemid 34097551)
33. Buckley MF, Sweeney KJ, Hamilton JA, Sini RL, Manning DL, Nicholson RI, et al. Expression and amplification of cyclin genes in human breast cancer. Oncogene 1993;8(8):2127-33. (Pubitemid 23226946)
34. Booy EP, Henson ES, Gibson SB. Epidermal growth factor regulates Mcl-1 expression through the MAPK-Elk-1 signalling pathway contributing to cell survival in breast cancer. Oncogene 2011;30(20):2367-78.
35. Yip KW, Reed JC. Bcl-2 family proteins and cancer. Oncogene 2008;27(50): 6398-406.
36. Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM, et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 2006;98(5): 326-34. (Pubitemid 43338212)
37. Rahmani M, Davis EM, Bauer C, Dent P, Grant S. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem 2005;280(42): 35217-27. (Pubitemid 41532709)
38. Reardon DA, Vredenburgh JJ, Desjardins A, Peters K, Gururangan S, Sampson JH, et al. Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. J Neurooncol 2011;101(1):57-66.
39. Isaacs C, Herbolsheimer P, Liu MC, Wilkinson M, Ottaviano Y, Chung GG, et al. Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer. Breast Cancer Res Treat 2011;125(1):137-43.
40. Hirth J, Watkins PB, Strawderman M, Schott A, Bruno R, Baker LH. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res 2000;6(4):1255-8. (Pubitemid 30226205)
41. Cresteil T, Monsarrat B, Dubois J, Sonnier M, Alvinerie P, Gueritte F. Regioselective metabolism of taxoids by human CYP3A4 and 2C8: structure-activity relationship. Drug Metab Dispos 2002;30(4):438-45. (Pubitemid 34263829)